Table 4. Multivariate analysis for risks of attrition over 12 months of follow up for patients presenting at an advanced stage.
| Crude | Adjusted | |||||
|---|---|---|---|---|---|---|
| HR | CI 95% | p value | HR | CI 95% | p value | |
| Age: | ||||||
| 19–24 | ref. | ref. | ref. | ref. | ref. | ref. |
| 24–40 | 0.79 | (0.66–0.96) | 0.0152 | 0.87 | (0.71–1.07) | 0.18213 |
| 40–60 | 0.81 | (0.67–0.99) | 0.0422 | 0.88 | (0.71–1.10) | 0.26745 |
| >60 | 1.3 | (0.96–1.77) | 0.0921 | 1.17 | (0.84–1.63) | 0.34707 |
| Sex: | ||||||
| Female | ref. | ref. | ref. | |||
| Male | 1.09 | (0.99–1.19) | 0.078 | |||
| Marital Status: | ||||||
| Married | ref. | ref. | ref. | ref. | ref. | ref. |
| Divorced | 1.1 | (0.95–1.27) | 0.187 | 0.93 | (0.80–1.09) | 0.36074 |
| Single | 1.39 | (1.19–1.64) | <0.001 | 1.17 | (0.98–1.39) | 0.07681 |
| Widowed | 1.28 | (1.14–1.45) | <0.001 | 1.04 | (0.92–1.19) | 0.52211 |
| Point of entry: | ||||||
| VCT | ref. | ref. | ref. | |||
| Health Care Facility | 0.97 | (0.83–1.12) | 0.645 | |||
| PMTCT | 1.06 | (0.84–1.35) | 0.62 | |||
| Other | 0.58 | (0.22–1.54) | 0.27 | |||
| Profession: | ||||||
| Employed | ref. | ref. | ref. | ref. | ref. | ref. |
| Unemployed | 0.8 | (0.72–0.89) | <0.001 | 0.99 | (0.88–1.11) | 0.87392 |
| Other | 0.76 | (0.63–0.90) | 0.00218 | 1.03 | (0.85–1.24) | 0.79496 |
| Year of enrolment: | ||||||
| 2007 | ref. | ref. | ref. | ref. | ref. | ref. |
| 2008 | 0.98 | (0.84–1.14) | 0.76781 | 1.37 | (1.17–1.59) | < 0.001 |
| 2009 | 0.65 | (0.52–0.80) | <0.001 | 1.24 | (1.00–1.54) | 0.04843 |
| 2010 | 0.52 | (0.44–0.62) | <0.001 | 1.62 | (1.34–1.96) | < 0.001 |
| 2011 | 0.51 | (0.43–0.61) | <0.001 | 1.77 | (1.46–2.15) | < 0.001 |
| 2012 | 0.53 | (0.44–0.64) | <0.001 | 1.55 | (1.26–1.90) | < 0.001 |
| 2013 | 0.67 | (0.55–0.82) | <0.001 | 2.17 | (1.74–2.71) | < 0.001 |
| 2014 | 0.93 | (0.76–1.14) | 0.49501 | 4.05 | (2.99–5.48) | < 0.001 |
| 2015 | 0.7 | (0.56–0.87) | 0.00116 | 2.67 | (1.82–3.91) | < 0.001 |
| 2016 | 1.06 | (0.82–1.38) | 0.64572 | 4.44 | (2.80–7.03) | < 0.001 |
| ART regimen: | ||||||
| TDF+3TC+EFV | ref. | ref. | ref. | ref. | ref. | ref. |
| D4T+3TC+EFV | 0.82 | (0.66–1.02) | 0.0763 | 1.61 | (1.18–2.20) | 0.00245 |
| D4T+3TC+NVP | 0.7 | (0.59–0.83) | <0.001 | 1.58 | (1.19–2.09) | 0.00156 |
| TDF+3TC+NVP | 0.6 | (0.47–0.77) | <0.001 | 0.78 | (0.56–1.09) | 0.15077 |
| AZT+3TC+NVP | 0.64 | (0.40–1.02) | 0.062 | 1.59 | (0.93–2.71) | 0.08858 |
| Other | 1.37 | (0.83–2.28) | 0.2208 | 2.56 | (1.46–4.49) | 0.00102 |
| Never initiated | 12.93 | (11.12–15.03) | <0.001 | 37.14 | (27.97–49.30) | < 0.001 |
| Enrolment CD4 count: | ||||||
| >200 | ref. | ref. | ref. | ref. | ref. | ref. |
| <10 | 1.96 | (1.59–2.41) | <0.001 | 2.97 | (2.37–3.73) | < 0.001 |
| 10 to 50 | 1.78 | (1.54–2.05) | <0.001 | 2.3 | (1.98–2.68) | < 0.001 |
| 50–100 | 1.18 | (1.01–1.37) | 0.0336 | 1.58 | (1.35–1.85) | < 0.001 |
| 100–200 | 0.88 | (0.77–1.01) | 0.0744 | 1.48 | (1.27–1.71) | < 0.001 |
| Tuberculosis diagnosis: | ||||||
| Not diagnosed | ref. | ref. | ref. | ref. | ref. | ref. |
| Within first 2 months | 0.48 | (0.41–0.55) | <0.001 | 1.18 | (0.96–1.45) | 0.12336 |
| Between 2 to 6 months | 0.49 | (0.36–0.68) | <0.001 | 1.15 | (0.79–1.66) | 0.47636 |
| Between 6 to 12 months | 0.22 | (0.12–0.41) | <0.001 | 0.64 | (0.33–1.25) | 0.19345 |
Cox proportional hazards regression analysis for risk of attrition in those with advanced HIV disease (Lost to follow up and death) over a period of 12 months of follow up. Complete case analysis approach used (n = 7260). Those variables not significant in the univariate analysis were dropped from the multivariate model.
Drug abbreviations; D4T: Stavudine, 3TC: Lamivudine, EFV: Efavirenz, NVP: Nevirapine, AZT: Zidovudine, TDF: Tenofovir.